This past November, Professor Ronald E. Pearlman from York University’s Department of Biology gave a talk [1] at Osgoode Hall Law School to discuss the potential of the innovative CRISPR…
Tag: pharmaceuticals
IP Intensive Program: Experiential Learning at Actavis
My 10 week internship at Actavis’ Canadian arm (formerly known as Cobalt), through Osgoode’s IP Intensive Program coincided with a very exciting time for the company. The company recently expanded…
Canada v. GSK - Intellectual Property Rights and the Arm's Length Principle
In an eagerly anticipated decision, the Supreme Court of Canada released its judgment on Canada v. GlaxoSmithKline Inc., 2012 SCC 52 (Glaxo SCC, affirming 2010 FCA 201 [Glaxo FCA]). (more…)
Allergan Inc. c. Canada (Health), 2012 FC 767: Comity or Tragedy?
A somewhat confusing victory for Allergan Inc. was won on June 18th, as the Honourable Justice Hughes upheld their patent on COMBIGAN despite the fact that their invention was ruled…
India’s First Compulsory Licence: Patents vs Public Health?
In a move with far reaching implications for the debates around pharmaceutical patents, innovation and access to medicines, the Indian patent office issued its first ever compulsory licence in the…
WHO Resolution Intended to Address Global Counterfeit Drug Market
On January 21, the WHO 130th WHO Executive Board (EB) adopted a resolution for agenda item 6.13 “substandard/spurious/falsely-labelled/falsified/counterfeit medical products” [SFFC]. The resolution is intended to address the growing prevalence…